For the millions of adults who achieve clinically meaningful weight loss on GLP-1/GIP receptor agonists, the real challenge begins at discontinuation — a pattern now being rigorously quantified. SURMOUNT-MAINTAIN directly addresses the most consequential question in obesity pharmacotherapy: what happens when the drug stops, and can a reduced dose preserve gains?
In this Phase 3b, 112-week Lancet trial, adults with obesity first completed a 60-week open-label tirzepatide weight-loss period reaching their maximum tolerated dose (10 mg or 15 mg weekly), then were randomized across 20 U.S. sites in a 3:3:2 ratio to continue at the maximum tolerated dose, step down to 5 mg, or switch to placebo for a further 52 weeks. Participants continuing at the maximum tolerated dose achieved a mean bodyweight reduction of approximately 20% from original baseline at week 112, compared with roughly 14% in the 5 mg step-down group and approximately 8% in those switched to placebo — with placebo participants regaining a substantial fraction of their prior losses. The between-group differences were statistically robust, and the safety profile remained consistent with prior tirzepatide trials.
This trial sits at a genuinely important junction in the obesity pharmacology literature. The weight regain observed after placebo switch — mirroring patterns seen in SURMOUNT-1 withdrawal analyses and the semaglutide STEP-4 trial — reinforces the emerging consensus that obesity functions more like a chronic relapsing condition requiring ongoing pharmacological support than a problem solved by a fixed treatment course. The 5 mg step-down arm is particularly clinically relevant: it suggests meaningful weight maintenance may be achievable at a lower, potentially better-tolerated dose, which could ease cost and adherence barriers at scale. Limitations include the U.S.-only population limiting generalizability, the open-label initial phase, and a relatively short 52-week maintenance window. Nonetheless, as a Phase 3b randomized controlled trial in a high-tier journal, this is confirmatory evidence with real prescribing implications — categorically above incremental.